Structural Studies of Amyloid
About the Research Project
Program
Award Type
Standard
Award Amount
$95,174
Active Dates
April 01, 1993 - March 31, 1995
Grant ID
A1993113
Summary
Alzheimer’s Disease (AD) is characterized by the presence of amyloid plaques within the brain. The core of these plaques has been shown to be composed primarily of a single kind of molecule, the ß amyloid protein. Surrounding the core is a region that contains dead and dying brain cells; the death of these cells is the cause of the progressive loss of brain function that occurs as the disease develops. It has been suggested that the amyloid plaques themselves cause the brain cells around them to die and so are the underlying cause of AD, although it is certainly possible that their formation is simply a by-product of the disease. There is a large amount of circumstantial evidence supporting the idea that the amyloid plaques are to blame. Our experiments are designed to examine what the ß amyloid protein molecules look like when they are packed up against each other in the plaque. We believe that this information could then be used to design agents which can bind to the plaques (and serve as an early diagnostic) and to design drugs that would bind to the ß amyloid molecules before they form a plaque, blocking plaque formation and so preventing AD.
Grants
Related Grants
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Alzheimer's Disease Research
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD